Cargando…
Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study
BACKGROUND: Clinical trials of tiotropium have principally recruited patients from secondary care with more severe chronic obstructive pulmonary disease (COPD), and typically had included limitation of concomitant medication. In primary care, which is the most common setting for COPD management, man...
Autores principales: | Freeman, Daryl, Lee, Angela, Price, David |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1913915/ https://www.ncbi.nlm.nih.gov/pubmed/17605774 http://dx.doi.org/10.1186/1465-9921-8-45 |
Ejemplares similares
-
Safety, tolerability and risk benefit analysis of tiotropium in COPD
por: Oba, Yuji, et al.
Publicado: (2008) -
Umberto Riva
por: Riva Umberto, 1928-
Publicado: (1993) -
Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007) -
Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009) -
Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden
por: Eklund, Oskar, et al.
Publicado: (2015)